Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes

被引：0
作者：
Yutaka Onishi
Takashi Fujisawa
Kazuhiko Sakaguchi
Mitsuo Maeda
机构：
[1] Harima Hospital of Ishikawajima-Harima Heavy Industries,Department of Internal Medicine
来源：
Advances in Therapy | 2006年 / 23卷
关键词：
LDL particle size; nateglinide; insulin resistance; postprandial hyperglycemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The objective of the present study was to evaluate the efficacy of nateglinide in controlling blood glucose levels and regulating lipid metabolism in patients with type 2 diabetes by focusing attention particularly on low-density lipoprotein (LDL) particle size. The subjects were 23 patients with type 2 diabetes who were given nateglinide, 90 to 270 mg/d. Laboratory studies were conducted at treatment initiation and 3 mo later. Despite a decline that occurred in the level of fasting plasma glucose before and after administration of nateglinide, no significant difference was recognized. Hemoglobin A1c decreased significantly from 6.37±0.75% to 5.91±0.64% (P<.001). A significant decline was also seen in the fasting level of immunoreactive insulin, from 9.82±5.69 μU/mL to 8.59±4.05 μU/mL (P<.05), and in the homeostasis model assessment for insulin resistance, from 3.0±1.83 to 2.55±1.26 (P<.05). Regarding lipids, triglycerides significantly decreased from 140.7±61.8 mg/dL to 117.3±34.7 mg/dL (P<.05). The significant reduction in migration index value, which was used as an index to LDL particle size, from 0.374±0.034 to 0.357±0.035 (P<.05), confirmed that LDL particle size had increased. The results of the present study show that nateglinide is effective in controlling blood glucose and improving insulin resistance, hypertriglyceridemia, and LDL particle size in patients with mild type 2 diabetes. These effects suggest that nateglinide may effectively control coronary artery disease in this population.
引用
收藏
页码：549 / 555
页数：6
相关论文
共 81 条
  • [1] Koba S(2000)Small dense low-density lipoprotein in Japanese men with coronary artery disease Ann Intern Med 132 762-762
  • [2] Hirano T(1988)Low-density lipoprotein subclass patterns and risk of myocardial infarction JAMA 260 1917-1921
  • [3] Austin MA(2002)Treatment of small dense LDL J Atheroscler Thromb 9 266-275
  • [4] Breslow JL(1998)Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 229-234
  • [5] Hennekens CH(1992)LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes Arterioscler Thromb 12 1496-1502
  • [6] Buring JE(1996)Risk factor for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up Diabetologia 39 1577-1583
  • [7] Willett WC(1999)Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnosis criteria Lancet 354 617-621
  • [8] Krauss RM(2000)Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnosis criteria Arch Intern Med 167 397-405
  • [9] Yoshino G(1985)Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 412-419
  • [10] Hirano T(2000)Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension J Diabetes Complications 14 135-139
123456789